Table 3.
Oncological and functional outcomes of the overall cohort.
| Authors | Median Follow-Up (Months) |
BCR n (%) | Recurrence Free Survival (RFS) (%) |
Cancer-Specific Survival (%) | Overall Survival (%) | Urinary Continence n (%) |
|---|---|---|---|---|---|---|
| Kaouk et al. (2008) [13] | 5 | NA | NA | NA | NA | At 1 month: 3 (75) |
| Liatsikos et al. (2008) [14] | Mean 20 | At 12 months: 1 (8) | NA | NA | NA | 10 (83) |
| Kim et al. (2008) [15] | NA | NA | NA | NA | NA | NA |
| Boris et al. (2009) [16] | 20.5 | At 43 months: 3 (30) | NA | NA | NA | 6 (54.5) |
| Seabra et al. (2009) [17] | 18 | NA | NA | NA | NA | 12 (28) |
| Leonardo et al. (2009) [18] | 35 | 8 (25) | NA | NA | NA | At 1 year: 0 pads per day: 7 (22) 1–2 pads per day: 20 (62.5)>2 pads per day: 5 (15.5) |
| Nunez-Mora et al. (2009) [19] | 26.8 | At 16 months: 2 (22) | NA | NA | NA | complete continence:3 (33) 1–2 pads per day:4 (44) |
| Paparel et al. (2009) [20] | 4.6 y | 65 (44.5) | 5 year: 54 | NA | NA | NA |
| Heidenreich et al. (2010) [21] | 23 | NA | NA | NA | NA | At 1 year: complete continence: 44 (80) |
| Strope et al. (2010) [22] | 15 | At 6 weeks: 2 (34) | NA | NA | NA | At 1 year: 2.3 pads per day: 4 (66) |
| Eandi et al. (2010) [23] | 18 | At 18 months: 2 (33) | NA | NA | NA | 6 (33) |
| Chauhan et al. (2011) [24] | 4.6 | At 5 months: 4 (28.6) | NA | NA | NA | 11 (71.4) |
| Chade et al. (2011) [25] | 4.4 y | At 5y: 48 | NA | At 10y: 83 | NA | NA |
| Gorin et al. (2011) [26] | 63 | At 2y: 14 (58) | 5 year: 40 | NA | 5 year: 90 | 23 (96) |
| Ahallal et al. (2011) [27] | 8 | NA | NA | NA | NA | 0 pads per day: 7 (47) 1–2 pads per day: 7 (47) |
| Lawrentschuk et al. (2011) [28] | NA | NA | NA | NA | NA | At 1 year:0 pads per day: 6 (60) |
| Leonardo et al. (2012) [29] | 14 | at 10 months: 1 (8) | NA | NA | NA | 0 pads per day: 9 (69)2 pads per day:4 (31) |
| Kaffenberger et al. (2013) [30] | 16.1 | At 16 months: 6 (18) | NA | NA | NA | 20 (65) |
| Peters et al. (2013) [31] | 60 | At 22 months: 29 (66 ) | NA | NA | NA | NA |
| Yuh et al. (2014) [32] | 36 | At 3 years: 57 | NA | NA | 5 year: 100 | At 6 month: 23 (45) |
| Zugor et al. (2014) [33] | 23 | 3 (23) | NA | NA | NA | At 12 month: 7 (54) |
| Saeedi et al. (2014) [34] | NA | NA | NA | NA | NA | At 12 month: 0 pads per day: 5 (83) 1 pads per day:1 (17) |
| Bates et al. (2015) [11] | 26 | At 13 months: 8 (15) | NA | NA | NA | At 36 month: 41 (77) |
| Pokala et al. (2015) [35] | NA | NA | NA | 10 years: 88.6 | 10 years: 77.5 | NA |
| Pearce et al. (2015) [36] | NA | NA | NA | NA | NA | NA |
| Lebdai et al. (2015) [37] | NA | NA | NA | NA | NA | At 10 month: Completely continent: 13 (68) ≤1 pad/day: 5 (27) 3 pads/day: 1 (5) |
| Mandel et al. (2016) [38] | 36 | 23 (42) | 5-year: 48.7 | NA | 5-year: 88.7 | 41 (74) |
| Vora et al. (2016) [39] | NA | NA | NA | NA | NA | 1 (16.7) |
| Kenney et al. (2016) [7] | 16.8 | NA | 9.5 months robotic | NA | NA | 4 (10) |
| Orré et al. (2016) [40] | NA | NA | NA | NA | NA | At 12 month: 4 (57) |
| Vidmar et al. (2017) [41] | 25 | NA | NA | NA | NA | 7 (30) |
| Metcalfe et al. (2017) [42] | 2.79 y | At 5 months: 35 (51.5) | Median: 2.78 | NA | NA | NA |
| Ogaya-Pinies et al. (2019) [43] | 14 | At 1 year: 15 (16) | NA | NA | NA | At 12 month: 0 pads per day: 55 (57) 1–2 pads per day: 25 (26) |
| Onol et al. (2019) [44] | 32 | 16 (17) Radiation group 6 (19) Focal ablation group |
5-year: 56 | NA | NA | At 1 year Overall full (no pads): 37 (39.2) social (0–1 pad/day): 48 (51.3) |
| Devos et al. (2019) [45] | 43 | NA | NA | 5-year: 74 | 5-year: 62 | 4 (16) |
| Mohler et al. (2019) [46] | 91 | NA | At 10y: 33 | NA | At 10y: 52 | At 12 year: 6 (15) |
| Clery et al. (2019) [47] | 24 | At 13 months: 17 (31) | NA | 5 years: 80 | NA | 27 (49.1) |
| Herrera-Caceres et al. (2019) [48] | 52 | At 42 months: 7 (21) | NA | NA | NA | ≤1 pad: 31 (91) ≥2 pads: 2 (6) |
| Gontero et al. (2019) [49] | 3 years | NA | NA | NA | NA | At 12 month: fully continent: 221 (56) |
| De Groote et al. (2020) [50] | 2.1 years | At 25 months: 26 (24) | 5-year: 60 | NA | NA | At 2 years or more fully continent: 53 (50) socially continent: 35 (33) |
| Nair et al. (2020) [51] | 43 | 2 (50) | NA | NA | NA | Continent:1 (25) 0–1 pads per day: 2 (50) |
| Thompson et al. (2020) [52] | 18 | At 3 months: 8 (16) | NA | NA | NA | Pad-free at 12-months: 35 (65.5) Socially continent at 12-mo (0–1 pad): 46 (86) |
| Nathan et al. (2021) [53] | 17 | At 26 months: 17 (33) | 5 years: 60 | NA | 129 (96) | At 12 month: fully continent: 90 (67) |
| Madi et al. (2021) [12] | 18 | NA | NA | NA | NA | 14 (100) |
| Rajwa et al. (2021) [54] | 25.3 | NA | NA | NA | NA | NA |
| Bozkurt et al. (2021) [55] | 32 | NA | NA | NA | NA | 0–1 pads per day: 2 (20) 2 pads per day: 6 (60) |
| Marra et al. (2021) [56] | 36 | At 12 months: 115 (31) | NA | 5 years: 98 | 5 years: 92 | 85 (28.2) |
| Spitznagel et al. (2021) [57] | 12 | At 12 months: 1 (8) | NA | NA | NA | No incontinence: 3 (20) Mild incontinence: 3 (20) Moderate incontinence: 6 (50) |
| Wenzel et al. (2021) [58] | 74 | NA | NA | 5 years: 13.4 | NA | NA |
| von Hardenberg et al. (2021) [59] | 28 | NA | 3 years: 80 | NA | NA | NA |
| Nathan et al. (2022) [60] | 16.5 | At 16.5 months: 31 (23) | 5 years: 75 | NA | NA | At 12 month: 77 (77) |
| Mortensen et al. (2022) [61] | 13 | NA | NA | NA | NA | 5 (100) |
| Van Riel et al. (2022) [62] | 17.7 | At 6 months: 1 (2.5) | NA | 100 | 100 | 34 (94.4) |
| Blazevski et al. (2022) [63] | 22 | At 22 months: 0 (0) | NA | NA | NA | Pad free at 3 months: 14 (93) Pad free at 6 months: 1 (7) |
| Catarino et al. (2022) [64] | 94 | At 61 months: 17 (59) | 5 years: 50 | NA | NA | At 12 month: Pad-free continence: 6 (21) Mild incontinence: 12 (41) |
NA: not available, RFS: recurrence-free survival, BCR: biochemical recurrence.